Cipla’s stock surged following Citi’s ‘Buy’ rating and a 90-day Positive Catalyst Watch. The brokerage anticipates growth from potential US approvals like gFlovent and gVentolin, alongside a rebound in its US business. Domestically, Cipla’s performance remains strong, supported by its respiratory portfolio. Citi sees earnings bottoming out and highlights attractive valuations for the Indian market.
© 2026 top-platforms.com | All Rights Reserved
Top-Platforms.com provides general market-related information, platform overviews, and educational content for informational purposes only. Nothing published on this website should be understood as investment advice, financial advice, or a direct recommendation to buy, sell, trade, or invest in any financial product.
Top-Platforms.com is not a broker, financial advisor, or investment firm, and does not provide brokerage services. Any decision to trade or invest is made at the user’s own discretion and risk. Financial markets involve risk, including the possible loss of capital, and users should carefully evaluate their personal situation before making any financial decision.
Information, prices, rankings, comparisons, and market data shown on this website may be delayed, incomplete, or subject to change without notice. Past performance, market trends, or platform features do not guarantee future results.
Top-Platforms.com may receive compensation from third-party advertisers, partners, or platforms displayed on this website. This compensation may influence how and where certain brands appear, but it does not constitute a financial recommendation.
This website and its content are not intended for residents of the United States, Canada, Australia, United Kingdom, Russia, North Korea, China, Japan, Hong Kong, Singapore, or Iran.
Top10 International FZ LLE | 17th Floor, Creative Tower | 4422 | Fujairah | TRN: 100608946800003